Immunosuppressive disease is independently associated with significantly shorter survival among patients with CSCC receiving ICI therapy.

Meta-analysis of data from FDA trials shows significantly improved OS, PFS, but increased risk for grade ≥3 adverse events compared with men.

The results of the 3-year follow-up show meaningful improvement in overall survival (OS) and progression-free survival (PFS) for tislelizumab plus chemotherapy compared with placebo plus chemotherapy.

Adding lenvatinib to pembrolizumab improved PFS (6.2 vs 2.8 months; HR 0.64) and ORR (46.1% vs 25.4%) versus pembrolizumab ...

Investigators delivered updated results from the phase 3 PHILA trial evaluating the pyrotinib or placebo plus trastuzumab and docetaxel in patients with untreated HER2+metastatic breast cancer.

Patients with multiple myeloma (MM) who have high-risk cytogenetic abnormalities typically have shorter progression-free survival (PFS) and overall survival (OS) compared with standard-risk patients.

This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This abstract does not include a full text component.

Findings showed datopotamab deruxtecan significantly improved PFS and OS vs chemotherapy. Topline data were announced from a phase 3 trial evaluating datopotamab deruxtecan-dlnk as a first-line ...

DATROWAY demonstrated statistically significant and clinically meaningful improvement in overall survival as 1st-line therapy for patients with metastatic triple-negative breast cancer for whom ...

A randomized phase 2 maintenance strategy with cabozantinib 60 mg daily for up to 2 years failed to improve 4-month PFS ...

Progression-free survival (PFS) only moderately correlates with overall survival (OS) at the individual and trial level in patients with HER2-positive metastatic breast cancer treated with ...